Theriva Biologics, Inc.

For the period ended Dec 31, 2025. Filed Mar 12, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 12, 2026

TOVX$0.17-0.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Page
	PART I.	3

Item 1.	Business	6

Item 1A.	Risk Factors	39

Item 1B.	Unresolved Staff Comments	72

Item 1C.	Cybersecurity	72

Item 2.	Properties	73

Item 3.	Legal Proceedings	73

Item 4.	Mine Safety Disclosures	73

	PART II.	74

Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	74

Item 6.	[Reserved]	74

Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	75

Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	84

Item 8.	Financial Statements and Supplementary Data	84

Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	128

Item 9A.	Controls and Procedures	128

Item 9B.	Other Information	129

Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	129

	PART III.	130

Item 10.	Directors, Executive Officers and Corporate Governance	130

Item 11.	Executive Compensation	133

Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	142

Item 13.	Certain Relationships and Related Transactions, and Director Independence	143

Item 14.	Principal Accountant Fees and Services	144

	PART IV.	145
Item 15.	Exhibits and Financial Statement Schedules	145

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Table of Contents